OverviewChartNewsTraderScreen

Citi Call 220 4AB 20.06.2024/  DE000KG56R53  /

EUWAX
6/3/2024  9:15:35 AM Chg.- Bid10:00:05 PM Ask10:00:05 PM Underlying Strike price Expiration date Option type
0.010EUR - -
Bid Size: -		 -
Ask Size: -		 ABBVIE INC. D... 220.00 - 6/20/2024 Call
GlobeNewswire 11:12 AM CEREVEL NEWS NOTIFICATION: BFA Law Alerts Cerevel (Nasdaq: CERE) Shareholders of Investigation into ...
GlobeNewswire 6/5 CEREVEL INVESTIGATION ALERT: Cerevel (Nasdaq: CERE) Investors are Encouraged to Contact BFA Law abou...
GlobeNewswire 6/5 Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors
GlobeNewswire 6/5 OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR...
GlobeNewswire 6/4 Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
GlobeNewswire 6/4 BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID
GlobeNewswire 6/3 Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
GlobeNewswire 6/3 ACQUISITION NEWS: Cerevel’s (Nasdaq: CERE) $45 Merger Offer is Being Investigated for Being Too Low,...
GlobeNewswire 6/1 CERE (NASDAQ) REMINDER: BFA Law Reminds Cerevel Shareholders to Inquire About Ongoing Investigation ...
GlobeNewswire 5/30 OSE Immunotherapeutics Provides Business and Corporate Update
GlobeNewswire 5/29 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach
GlobeNewswire 5/28 Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Imp...
GlobeNewswire 5/28 CEREVEL THERAPEUTICS ALERT: Cerevel’s $45 Merger Offer From AbbVie is Under Investigation (Nasdaq: C...
GlobeNewswire 5/28 Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
GlobeNewswire 5/25 CERE (NASDAQ) ALERT: Cerevel’s $45 Merger Offer From AbbVie is Under Investigation; Contact BFA Law ...
GlobeNewswire 5/24 Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7...
GlobeNewswire 5/23 Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine recept...
GlobeNewswire 5/22 Over 130 Resident Dermatologists Receive In-Depth Cosmetic Training From Renowned ASDS Member Physic...
GlobeNewswire 5/22 Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $57...
GlobeNewswire 5/22 CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference
GlobeNewswire 5/22 Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $57...
GlobeNewswire 5/22 Anavex Life Sciences Announces Expansion of Leadership Team
GlobeNewswire 5/22 OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treat...
GlobeNewswire 5/21 COUR Pharmaceuticals Appoints Paul M. Peloso, MD, as Chief Medical Officer
GlobeNewswire 5/21 BREAKING CEREVEL INVESTIGATION: BFA Law Is Investigating the $45 Per CERE (Nasdaq) Share Offer by Ab...